journal
https://read.qxmd.com/read/37711639/shared-decision-making-a-personal-view-from-two-kidney-doctors-and-a-patient
#1
REVIEW
Barnaby Hole, Miranda Scanlon, Charlie Tomson
Shared decision making (SDM) combines the clinician's expertise in the treatment of disease with the patient's expertise in their lived experience and what is important to them. All decisions made in the care of patients with kidney disease can potentially be explored through SDM. Adoption of SDM in routine kidney care faces numerous institutional and practical barriers. Patients with chronic disease who have become accustomed to paternalistic care may need support to engage in SDM-even though most patients actively want more involvement in decisions about their care...
September 2023: Clinical Kidney Journal
https://read.qxmd.com/read/37711638/the-role-of-low-health-literacy-in-shared-treatment-decision-making-in-patients-with-kidney-failure
#2
REVIEW
Néstor Toapanta, Karla Salas-Gama, Percy Efrain Pantoja, María José Soler
The classic paternalist medicine in nephrology has been modified to a shared decision-making model that clearly offers a benefit in patients with kidney disease. One of the cornerstones of shared treatment decision in patients with kidney failure is the understanding of kidney disease. As kidney disease is silent until advanced stages and is also an entity with a complex pathophysiology with little knowledge in the general population, its presence and understanding are difficult for most people. Health literacy (HL) plays a crucial role in the care of patients with kidney disease and the shared treatment decision...
September 2023: Clinical Kidney Journal
https://read.qxmd.com/read/37711637/a-learning-process-to-deliver-virtual-staff-training-involving-patients-in-shared-haemodialysis-care
#3
REVIEW
Tania Barnes, Martin Wilkie
Shared haemodialysis (HD) care (SHC) is a person-centred approach delivering a flexible choice of options for centre-based HD patients to become more involved in their treatment. To support this, a 4-day course was developed to provide healthcare professionals with the confidence and skills to engage, involve, support and train patients in their care and has been accessed by >700 UK staff over 9 years. The disruption caused by the coronavirus disease 2019 pandemic in 2020 prompted a revision of what was deliverable within the restrictions...
September 2023: Clinical Kidney Journal
https://read.qxmd.com/read/37711636/partnering-with-patients-and-caregivers-to-enrich-research-and-care-in-kidney-disease-values-and-strategies
#4
REVIEW
Rosanna Cazzolli, Amanda Sluiter, Chandana Guha, Brooke Huuskes, Germaine Wong, Jonathan C Craig, Allison Jaure, Nicole Scholes-Robertson
Patient and caregiver involvement broadens the scope of new knowledge generated from research and can enhance the relevance, quality and impact of research on clinical practice and health outcomes. Incorporating the perspectives of people with lived experience of chronic kidney disease (CKD) affords new insights into the design of interventions, study methodology, data analysis and implementation and has value for patients, healthcare professionals and researchers alike. However, patient involvement in CKD research has been limited and data on which to inform best practice is scarce...
September 2023: Clinical Kidney Journal
https://read.qxmd.com/read/37711635/an-update-on-absolute-and-relative-indications-for-dialysis-treatment-modalities
#5
REVIEW
Mark Lambie, Simon Davies
BACKGROUND: Choosing a dialysis modality is an important decision for people to make as their kidney failure progresses. In doing so, their options should be informed by any absolute or relative indications that may favour one modality over another. METHODS: In creating this update, we reviewed literature using a framework that considered first, high-level outcomes (survival and modality transition) from large registry data and cohort studies when considering optimal patient pathways; second, factors at a dialysis provider level that might affect relative indications; and third, specific patient-level factors...
September 2023: Clinical Kidney Journal
https://read.qxmd.com/read/37711634/decision-aids-to-assist-patients-and-professionals-in-choosing-the-right-treatment-for-kidney-failure
#6
REVIEW
Hilary L Bekker, Anna E Winterbottom, Teresa Gavaruzzi, Jeanette Finderup, Andrew Mooney
BACKGROUND: Kidney services vary in the way they involve people with kidney failure (PwKF) in treatment decisions as management needs change. We discuss how decision-science applications support proactively PwKF to make informed decisions between treatment options with kidney professionals. METHODS: A conceptual review of findings about decision making and use of decision aids in kidney services, synthesized with reference to: the Making Informed Decisions-Individually and Together (MIND-IT) multiple stakeholder decision makers framework; and the Medical Research Council-Complex Intervention Development and Evaluation research framework...
September 2023: Clinical Kidney Journal
https://read.qxmd.com/read/37711633/involving-patients-in-treatment-decisions-disease-management-and-research-for-end-stage-kidney-disease
#7
EDITORIAL
Kitty J Jager, Sabine N van der Veer
No abstract text is available yet for this article.
September 2023: Clinical Kidney Journal
https://read.qxmd.com/read/37669312/anti-cd20-should-be-the-first-line-treatment-in-high-risk-membranous-nephropathy
#8
JOURNAL ARTICLE
Ladan Zand, Fernando C Fervenza
Membranous nephropathy (MN) is a common cause of nephrotic syndrome (NS) in adults and if untreated can progress to endstage kidney disease. Factors considered to place a patient at high or very high risk for progression include elevated serum creatinine at baseline, declining kidney function, persistent heavy proteinuria (>8 g/24 h), or persistent NS, presence of life-threatening complications related to NS (such as venous thromboembolic events), or very high anti-PLA2R antibody titers (>150 RU/ml)...
September 2023: Clinical Kidney Journal
https://read.qxmd.com/read/37669306/the-place-of-cyclical-therapy-for-the-treatment-of-membranous-nephropathy-in-the-era-of-rituximab
#9
JOURNAL ARTICLE
Federico Alberici, Federica Mescia, Francesco Scolari
Primary membranous nephropathy (MN) is the most frequent cause of nephrotic syndrome in adults, due to a variety of autoantibodies, most frequently against phospholipase A2 receptor (PLA2R). In severe cases or when spontaneous remission is not achieved, immunosuppression is required. Cyclical therapy, based on glucocorticoids and cyclophosphamide on alternate months for 6 months, has proven effective to induce remission and reduce the risk of end-stage renal disease. Since the early 2000s, rituximab (RTX) has emerged as a key player in the management of MN, showing overall comparable effectiveness and likely better safety compared with the cyclical regimen, despite the lack of adequately powered trials comparing the two approaches head to head...
September 2023: Clinical Kidney Journal
https://read.qxmd.com/read/37664579/single-institution-prescribing-pattern-of-finerenone-in-patients-with-type-2-diabetes-and-or-chronic-kidney-disease-in-the-usa
#10
JOURNAL ARTICLE
Rong M Zhang
No abstract text is available yet for this article.
September 2023: Clinical Kidney Journal
https://read.qxmd.com/read/37664578/safety-and-efficacy-of-pre-exposure-prophylaxis-with-tixagevimab-cilgavimab-evusheld-in-patients-with-glomerular-diseases-who-received-rituximab
#11
JOURNAL ARTICLE
Savino Sciascia, Maria Letizia Antonietta Rilat, Roberta Fenoglio, Silvia Grazietta Foddai, Massimo Radin, Irene Cecchi, Giacoma Cinnirella, Paola Crosasso, Maria Gabriella Guidetti, Alice Barinotti, Simone Baldovino, Elisa Menegatti, Dario Roccatello
BACKGROUND: Patients on B-cell-depleting agents may have a suboptimal response to vaccination, placing them at a higher risk of contracting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or suffering from a more severe prognosis. Indeed, available data on pre-exposure prophylaxis with tixagevimab/cilgavimab (Evusheld) in subjects with glomerular diseases (GDs) who received rituximab are limited. METHODS: We conducted a prospective study analysing the safety and efficacy of tixagevimab/cilgavimab for pre-exposure prophylaxis in patients with GDs who received rituximab in the previous 12 months...
September 2023: Clinical Kidney Journal
https://read.qxmd.com/read/37664577/a-new-immune-disease-systemic-hypertension
#12
REVIEW
Sidar Copur, Ibrahim B Peltek, Ali Mutlu, Cem Tanriover, Mehmet Kanbay
Systemic hypertension is the most common medical comorbidity affecting the adult population globally, with multiple associated outcomes including cerebrovascular diseases, cardiovascular diseases, vascular calcification, chronic kidney disease, metabolic syndrome and mortality. Despite advancements in the therapeutic field approximately one in every five adult patients with hypertension is classified as having treatment-resistant hypertension, indicating the need for studies to provide better understanding of the underlying pathophysiology and the need for more therapeutic targets...
September 2023: Clinical Kidney Journal
https://read.qxmd.com/read/37664576/clinical-and-immunological-characteristics-of-patients-with-combined-anti-glomerular-basement-membrane-disease-and-iga-nephropathy
#13
JOURNAL ARTICLE
Cong-Rong Shen, Xiao-Yu Jia, Zhao Cui, Xiao-Juan Yu, Ming-Hui Zhao
BACKGROUND: The combination of anti-glomerular basement membrane (GBM) disease and immunoglobulin A nephropathy (IgAN) has been well documented in sporadic cases, but lacks overall assessment in large collections. Herein, we investigated the clinical and immunological characteristics and outcome of this entity. METHODS: Seventy-five consecutive patients with biopsy-proven anti-GBM disease from March 2012 to March 2020 were screened. Among them, patients with concurrent IgAN were identified and enrolled...
September 2023: Clinical Kidney Journal
https://read.qxmd.com/read/37664575/diagnosis-and-treatment-of-lupus-nephritis-a-summary-of-the-consensus-document-of-the-spanish-group-for-the-study-of-glomerular-diseases-glosen
#14
REVIEW
Jorge E Rojas-Rivera, Clara García-Carro, Ana I Ávila, Mar Espino, Mario Espinosa, Gema Fernández-Juárez, Xavier Fulladosa, Marian Goicoechea, Manuel Macía, Enrique Morales, Luis F Quintana, Manuel Praga
Lupus nephritis (LN) is the most frequent serious manifestation of patients with systemic lupus erythematosus (SLE). Up to 60% of SLE patients develop LN, which has a significant impact on their quality of life and prognosis. Recent advances have improved the diagnostic approach to LN, and new drugs that block specific pathways and kidney damage progression have been developed. Several randomized and well-powered clinical trials have confirmed the efficacy of these agents in terms of proteinuria remission and preservation of kidney function in the medium and long term, with an acceptable safety profile and good tolerance...
September 2023: Clinical Kidney Journal
https://read.qxmd.com/read/37664574/new-and-old-gfr-equations-a-european-perspective
#15
REVIEW
Pierre Delanaye, Etienne Cavalier, Hans Pottel, Thomas Stehlé
Glomerular filtration rate (GFR) is estimated in clinical practice from equations based on the serum concentration of endogenous biomarkers and demographic data. The 2009 creatinine-based Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI2009 ) was recommended worldwide until 2021, when it was recalibrated to remove the African-American race factor. The CKD-EPI2009 and CKD-EPIcr2021 equations overestimate GFR of adults aged 18-30 years, with a strong overestimation in estimated GFR (eGFR) at age 18 years...
September 2023: Clinical Kidney Journal
https://read.qxmd.com/read/37664573/shedding-a-light-on-sex-disparity-in-clinical-trials-in-ckd-patients
#16
EDITORIAL
Francesca Mallamaci, Giovanni Tripepi
Clinical studies do not include an adequate proportion of female participants, and research data on drug efficacy and safety are generally collected from studies including a majority of men and extrapolated to women. This article describes the imbalance of male and female distribution in clinical studies, including patients with chronic kidney disease. The lack of sex equity in clinical research is a real 'public health problem' because not reporting sex-specific results may result in the loss of information on how a drug works according to sex...
September 2023: Clinical Kidney Journal
https://read.qxmd.com/read/37664572/novel-equations-for-estimating-intraperitoneal-pressure-among-peritoneal-dialysis-patients
#17
JOURNAL ARTICLE
Xinqiu Li, Tiantian Ma, Jiayu Hao, Di Song, Hongyan Wang, Tianjiao Liu, Yaling Zhang, Nanzha Abi, Xiao Xu, Manze Zhang, Weiqi Sun, Xin Li, Jie Dong
BACKGROUND: Increased intraperitoneal pressure (IPP) is associated with abdominal wall complications and technical failure in peritoneal dialysis (PD). Since the standard measurement of IPP is limited due to its cumbersome procedures, we aimed to develop and validate equations for estimating IPP. METHODS: We performed a cross-sectional study with a total of 200 prevalent PD patients who were divided into development and validation datasets after random sampling matched by body mass index...
September 2023: Clinical Kidney Journal
https://read.qxmd.com/read/37664571/kidney-stones-and-thiazide-diuretics-revisiting-old-assumptions-in-light-of-the-nostone-trial
#18
Luigi Cirillo, Francesca Becherucci, Martin Windpessl
No abstract text is available yet for this article.
September 2023: Clinical Kidney Journal
https://read.qxmd.com/read/37664570/radiation-nephropathy-is-associated-with-a-glomerular-thrombotic-microangiopathy-and-progression-to-end-stage-kidney-disease
#19
Isabela Bertoni, Maria F Soares, Ian S D Roberts, Thomas Connor
Radiation nephropathy is a rare complication following total body irradiation (TBI) and peptide receptor radionuclide therapy (PRRT). Yttrium 90-DOTATOC (Y90) is a somatostatin analogue labelled with Y90 used for somatostatin-positive neuroendocrine tumours. Y90 is renally excreted and has a cumulative effect in the renal parenchyma Despite fractionation and co-administration of renoprotective intravenous amino acids, targeted radionuclide therapy can still be nephrotoxic. Rising adoption of PRRT has led to the re-emergence of radiation nephropathy...
September 2023: Clinical Kidney Journal
https://read.qxmd.com/read/37664569/integrative-analysis-of-the-association-between-circadian-rhythm-and-lupus-nephritis
#20
JOURNAL ARTICLE
Meiling Jin, Fei Teng, Baoping Cao, Qianmei Sun, Diangeng Li
BACKGROUND: Lupus nephritis (LN) is an autoimmune nephropathy associated with systemic lupus erythematosus. Circadian rhythms are involved in the development of several diseases, especially inflammation-related diseases, but their relationship with LN is unclear. METHODS: This was an integrative bioinformatics study. The expression profile from glomeruli, tubular interstitium and renal whole tissue samples was used to assess the expression levels and relevance of circadian rhythm-related genes...
September 2023: Clinical Kidney Journal
journal
journal
43966
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.